CTLA4 and myeloid sarcoma: In addition, Wang et al. have evaluated the plasma concentrations of the soluble form of CTLA-4 (sCTLA-4) in MS patients, neuromyelitis optica (NMO) patients, and controls, and they found that the levels of sCTLA-4 were decreased in MS patients in comparison to the controls and that sCTLA-4 did not correlate with the EDSS score in MS and NMO patients [83].